A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Trial Profile

A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Elosulfase alfa (Primary)
  • Indications Mucopolysaccharidosis IV
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 24 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 May 2014 EudraCT reports trial status as recruiting.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top